Palbociclib was the first inhibitor of CDK4/6 to receive an accelerated approval by the Food and Drug Administration (FDA) in February 2015, in combination with letrozole as initial therapy for AI-sensitive advanced or metastatic BC, based on results from PALOMA-1 and PALOMA-2 trials [19,20,21]. The gene discussed is CDK4; the disease is breast cancer.